Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 20, 2014

Primary Completion Date

July 9, 2021

Study Completion Date

July 9, 2021

Conditions

Graft vs Host Disease

Interventions

DRUG

Atorvastatin calcium

40 mg PO daily

Trial Locations (2)

West Virginia University Hospitals Mary Babb Randolph Cancer Center, Morgantown

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

All Listed Sponsors

collaborator

West Virginia University

OTHER

lead

Mehdi Hamadani

OTHER

NCT01665677 - Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation | Biotech Hunter | Biotech Hunter